Lifeward Ltd. a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced it has entered into a definitive agreement to acquire certain technology assets and related know-how, including functional prototypes from Skelable Ltd., the developer of a robotic upper body orthotic device with AI capabilities, for total consideration of $480,000 in Lifeward equity, payable in installments upon the achievement of specified milestones, and a nominal cash payment at closing.

Lifeward有限公司，一家全球领先的创新医疗技术企业，致力于通过其技术改变有身体限制或残疾的人们的生活，今日宣布已达成一项最终协议，将以总计480,000美元的Lifeward股权收购Skelable有限公司的特定技术资产及相关专有知识，包括功能原型。Skelable有限公司是一家开发具备人工智能能力的机器人上半身矫形设备的公司。收购款项将按达成特定里程碑分期支付，并在交割时支付少量现金。

As part of the acquisition, the key engineering team will join Lifeward, bringing more than 60 years of combined experience across electrical, software, mechanical and industrial design. The integration of the core engineering team will ensure continuity of knowledge and a disciplined transfer of technology, intellectual property and design intent into Lifeward’s development framework..

作为收购的一部分，核心工程团队将加入Lifeward，带来超过60年的电气、软件、机械和工业设计综合经验。核心工程团队的整合将确保知识的连续性，并将技术、知识产权和设计意图有条不紊地转移到Lifeward的开发框架中。

The acquired technology will enable commercialization of a powered upper-extremity orthotic system designed to assist and enhance functional movement in individuals with weakened or paralyzed arms and hands, primarily following stroke. The device is intended to enable patients to perform activities of daily living that may otherwise be impossible, while supporting therapeutic goals such as muscle re-education and improved range of motion..

所获得的技术将有助于商业化一种动力上肢矫形系统，该系统旨在帮助和增强中风后手臂和手部虚弱或瘫痪者的功能性运动。该设备旨在使患者能够完成日常生活中原本可能无法完成的活动，同时支持诸如肌肉再教育和扩大活动范围等治疗目标。

Lifeward expects the new upper body exoskeleton to be ready for commercial launch within approximately 18 to 24 months, following additional development and regulatory approvals, and anticipates attractive gross margins and favorable unit economics over time.

Lifeward预计，新的上半身外骨骼将在大约18到24个月内完成进一步开发和监管审批后实现商业发布，并预计随着时间推移将实现可观的毛利率和良好的单位经济效益。

“This upper-limb orthotic technology is a natural extension of our ReWalk® platform and accelerates Lifeward’s evolution into a fully integrated, whole-body neuro-rehabilitation company,” said Mark Grant, President and CEO of Lifeward. “The device is designed not only to support immediate functional movement, but to rehabilitate and restore independence over time.

“这种上肢矫形技术是我们ReWalk®平台的自然延伸，也加速了Lifeward向全集成式全身神经康复公司的演变，” Lifeward总裁兼首席执行官马克·格兰特表示。“该设备不仅旨在支持即时的功能性运动，还致力于随着时间推移进行康复并恢复患者的独立性。”

This acquisition expands our addressable market, enhances commercial efficiency through shared channels, and strengthens our position across payers and prescribers. We are also adding exceptional engineering talent that will significantly expand our internal R&D capabilities and accelerate innovation across our platform.”.

此次收购扩大了我们的可触达市场，通过共享渠道提高了商业效率，并加强了我们在支付方和处方方的市场地位。我们还引入了卓越的工程人才，这将显著扩展我们内部的研发能力，并加速我们平台上的创新。

“What differentiates this technology is how intentionally it is designed around the human experience,” said David Hexner, Vice President of Research and Development at Lifeward. “Built on a strong intellectual property foundation, the system integrates advanced sensing and intelligent and adaptive control with an intuitive, patient-focused design that prioritizes usability and comfort.

“这项技术的不同之处在于它是如何围绕人类体验进行有意设计的，”Lifeward研发副总裁大卫·赫克斯纳表示。“该系统建立在强大的知识产权基础上，将先进的传感技术和智能自适应控制与直观、以患者为中心的设计相结合，优先考虑了可用性和舒适性。”

The result is a next-generation rehabilitation platform that delivers personalized and responsive therapy while maintaining medical-grade performance, safety and reliability.”.

结果是一个下一代的康复平台，它在保持医疗级性能、安全性和可靠性的同时，提供个性化且响应迅速的治疗。

This acquisition represents a strategic expansion into a significant market opportunity in upper-limb impairment following stroke, a substantial and underserved market where Lifeward can enhance wellbeing and quality of life. In the U.S. alone, 245,000 newly diagnosed stroke survivors each year experience functional impairments that may make them candidates for upper-limb neuro-rehabilitation technologies.

此次收购代表了战略性的扩展，进入了中风后上肢损伤这一重要市场机遇。这是一个庞大且服务不足的市场，Lifeward可以提高患者的生活福祉和生活质量。仅在美国，每年就有24.5万名新诊断的中风幸存者经历可能使他们成为上肢神经康复技术候选者的功能障碍。

Additionally, of the more than 7 million stroke survivors in the U.S., approximately two-thirds remain disabled, representing an estimated 4.6 million individuals in the prevalence-based addressable population..

此外，在美国超过700万的中风幸存者中，约有三分之二的人仍然残疾，这代表着在基于患病率的可治疗人群中，大约有460万人。

Compelling commercial synergies between the acquired upper-body exoskeleton and the Company’s lead product, ReWalk, include a crossover in prescriber groups, including physical medicine and rehabilitation (PM&R) physicians, neurologists, and stroke specialists, as well as rehabilitation settings such as inpatient and outpatient neuro-rehabilitation centers and Veterans Affairs facilities.

收购的上肢外骨骼与公司主导产品ReWalk之间存在引人注目的商业协同效应，包括处方医生群体的交叉，例如物理医学与康复（PM&R）医生、神经科医生和中风专家，以及康复环境的重叠，如住院和门诊神经康复中心以及退伍军人事务设施。

The overlap in payer segments further enhances the potential for commercial leverage and scalable go-to-market execution. Lifeward expects these synergies to support efficient commercialization, strengthen institutional relationships, and improve long-term negotiating leverage with payers..

付款方细分市场的重叠进一步增强了商业杠杆潜力和可扩展的上市执行能力。Lifeward 期望这些协同效应能够支持高效的商业化，加强机构关系，并提升与付款方的长期谈判杠杆。

Lifeward believes that this upper-limb orthotic program is well positioned within existing U.S. reimbursement frameworks for advanced assistive and neuro-rehabilitation technologies. The Company expects to leverage established Centers for Medicare & Medicaid Services (CMS) pathways applicable to upper-extremity powered orthoses and robotic assistive devices, including HCPCS coding structures introduced for upper-limb exoskeleton and neuro-robotic technologies, together with applicable CMS payment determination mechanisms..

Lifeward认为，此上肢矫形项目在美国现有的先进辅助和神经康复技术的报销框架中占据有利位置。公司计划利用已建立的适用于上肢动力矫形器和机器人辅助设备的医疗保险和医疗补助服务中心（CMS）途径，包括为上肢外骨骼和神经机器人技术引入的HCPCS编码结构，以及适用的CMS支付决定机制。

Beyond stroke rehabilitation, this acquisition positions Lifeward to expand into adjacent neurological and neuromuscular conditions, including upper-limb spinal cord injury, traumatic brain injury, multiple sclerosis, brachial plexus injury, and peripheral nerve injury-each representing meaningful unmet clinical need and incremental commercial opportunity..

除了中风康复之外，此次收购使Lifeward能够扩展到相邻的神经和神经肌肉疾病领域，包括上肢脊髓损伤、创伤性脑损伤、多发性硬化症、臂丛神经损伤和周围神经损伤——每种疾病都代表着显著的未满足临床需求和渐进的商业机会。

The transaction is contingent upon customary closing conditions.

该交易取决于惯例的成交条件。

The securities to be issued in connection with the transactions described herein are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements..

本文所述交易中将要发行的证券是在非公开发行的交易中进行的，且尚未根据修订后的《1933年证券法》进行注册，除非依据有效的注册声明或适用的注册要求豁免，否则不得在美国境内发售或出售。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他司法管辖区进行这些证券的销售，因为在该等州或其他司法管辖区，此类要约、邀请或销售在根据其证券法进行注册或资格认证之前是非法的。

To learn more about the Lifeward mission and product portfolio, please visit GoLifeward.com.

要了解有关Lifeward使命和产品组合的更多信息，请访问GoLifeward.com。

About Lifeward

关于Lifeward

Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities.

Lifeward 设计、开发并推广改变生活的解决方案，涵盖物理康复和恢复的整个护理过程，在临床环境以及家庭和社区中提供经过验证的功能性和健康益处。Lifeward 的使命是不懈推动创新，以改变身体受限或残疾人士的生活。

We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity systems, the ReStore Exo-Suit, and the MyoCycle FES Systems..

我们致力于提供开创性的解决方案，使个人能够从事他们热爱的事业。Lifeward 产品组合包括创新产品，如 ReWalk 外骨骼、AlterG 反重力系统、ReStore 外套和 MyoCycle 功能性电刺激系统。

Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward product portfolio, please visit GoLifeward.com.

Lifeward 成立于2001年，在美国、以色列和德国设有业务。如需了解 Lifeward 产品组合的更多信息，请访问 GoLifeward.com。

ReWalk®, ReStore® and Alter G® are registered trademarks of ReWalk Robotics Ltd. (DBA Lifeward) and/or its affiliates.

ReWalk®、ReStore® 和 Alter G® 是 ReWalk Robotics Ltd.（DBA Lifeward）及其关联公司的注册商标。

Forward-Looking Statements

前瞻性声明

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward looking statements may include statements regarding the acquisition of assets from Skelable Ltd.

本新闻稿除包含历史信息外，还包含1995年美国《私人证券诉讼改革法案》、1933年美国《证券法》第27A条以及1934年美国《证券交易法》第21E条所指的前瞻性陈述。这些前瞻性陈述可能包括有关从Skelable Ltd.收购资产的声明。

(the “Proposed Acquisition”), projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like 'anticipate,' 'assume,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'future,' 'will,' 'should,' 'would,' 'seek' and similar terms or phrases.

（“拟议收购”）、关于公司未来业绩的预测以及其他并非历史事实的陈述，在某些情况下，可能通过诸如“预期”、“假设”、“相信”、“继续”、“可能”、“估计”、“预计”、“打算”、“或许”、“计划”、“潜力”、“预测”、“展望未来”、“将”、“应该”、“会”、“寻求”等词语或类似术语或短语来识别。

The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward looking statements include, among others: the ability of the parties to consummate the Proposed Acquisition in a timely manner or at all, including the ability of the parties to satisfy the closing conditions set forth in the transaction agreement, Lifeward’s ability to realize the anticipated benefits of the Proposed Acquisition, including the possibility that the expected benefits of the Proposed Acquisition will not be realized within the expected time period or at all, potential delays in consummating the Proposed Acquisition, the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare pro.

本新闻稿中包含的前瞻性陈述基于管理层的当前预期，这些预期存在不确定性、风险以及难以预测且许多情况超出公司控制范围的变化。可能导致公司实际结果与前瞻性陈述中所示有重大差异的重要因素包括但不限于：各方能否及时完成拟议收购，或根本无法完成，包括各方能否满足交易协议中规定的交割条件；Lifeward 能否实现拟议收购的预期收益，包括拟议收购的预期收益可能无法在预期时间内实现或根本无法实现的可能性；完成拟议收购的潜在延迟；医疗专业人士对 ReWalk 7 个人外骨骼的接受程度等。

Contact:

联系：

Almog Adar

阿尔莫格·阿达尓

Chief Financial Officer

首席财务官

Lifeward

生命守护

E:

E:

[email protected]

电子邮件地址

E:

E:

[email protected]

电子邮件地址

Source: globenewswire.com

来源：globenewswire.com